Abstracts tagged "Hepatitis C"

Abstract Number: 948 • 2019 ACR/ARP Annual Meeting
Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study
Mohamed Tharwat Hegazy¹, Ahmed Fayed ¹, Tarek El Shabony ¹, Marcella Visentini ², David Saadoun ³, Patrice Cacoub ³ and Gaafar Ragab ¹, ¹Cairo University, Cairo, Egypt, Cairo, Egypt, ²Sapienza University of Rome, Rome, Italy, Rome, Italy, ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) combinations proved to be effective for the treatment of HCV induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of…
Abstract Number: 2101 • 2019 ACR/ARP Annual Meeting
Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Matthew Malus¹, Ly-Elaine Pham ¹, Hrishikesh Samant ¹ and Mamatha Katikaneni ², ¹Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, ²LSUHSC- Shreveport, Shreveport, LA
Background/Purpose: Chronic Hepatitis C virus infection (HCV) has been shown to be associated with connective tissue diseases (CTD). It has been hypothesized that HCV can…
Abstract Number: 829 • 2018 ACR/ARHP Annual Meeting
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs
Mohamed Tharwat Hegazy¹, Walaa Allam², Mohamed A Hussein¹, Naguib Zoheir³, Luca Quartuccio⁴, Patrice Cacoub⁵, Wahid Doss⁶, Mona I. Ellawindi⁷, Mary Fawzy¹, Loïc Guillevin⁸, Ahmed El Ray⁹, Maissa El Said El Raziky^10,11, Magdy El Serafy⁶, Sherif El Khamisy^2,12 and Gaafar Ragab¹, ¹Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Center for Genomics, Zewail City of Science and Technology, Giza, Egypt, Giza, Egypt, ³Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁶Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁷Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁸Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁹Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ¹⁰Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ¹¹Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ¹²Krebs Institute, University of Sheffield, Sheffield, S10 2TN, UK, Sheffield, United Kingdom
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs Background/Purpose: Direct Acting Antiviral (DAA) agents were shown to be effective…
Abstract Number: 831 • 2018 ACR/ARHP Annual Meeting
No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response
Patrice Cacoub¹, Eve Todesco², Pascale Ghillani-Dalbin³, Lucile Musset³ and David Saadoun⁴, ¹Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ²Virology Pitie Salpetriere hospital, Paris, France, ³Immunobiology department Pitie Salpetriere Hospital, Paris, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
No more HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after DAA-induced Sustained Virological ResponseBackground/Purpose: In addition to high antiviral efficacy,…
Abstract Number: 1479 • 2018 ACR/ARHP Annual Meeting
The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias
Divya Jayakumar^1,2, Xinliang Huang^1,2, Seth Eisen^1,2, Prabha Ranganathan^1,2 and Amy Joseph^2,3, ¹Rheumatology, VA St. Louis Health Care System, St Louis, MO, ²Rheumatology, Washington University School of Medicine, St Louis, MO, ³Rheumatology, VA St. Louis Health Care System, St. Louis, MO
Background/Purpose: Joint pain is a common extra-hepatic manifestation of chronic hepatitis C (HCV) infection. HCV infection is often associated with the presence of autoantibodies such…
Abstract Number: 1355 • 2017 ACR/ARHP Annual Meeting
14-3-3η: Useful for More Than the Diagnosis of Rheumatoid Arthritis?
Lisa Zickuhr¹, Maryam Pourpaki², Martha M. Brooks³ and Amy Joseph⁴, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatology, Advocate Christ Medical Center at Chicago, Oak Lawn, IL, ³Rheumatology, St. Louis VA Medical Center, St. Louis, MO, ⁴Rheumatology, Veterans Administration Central Office, St. Louis, MO
Background/Purpose: Chronic hepatitis C virus (HCV) infection can masquerade as rheumatoid arthritis (RA). Distinguishing between the two is important because treatments differ. 14-3-3η has been…
Abstract Number: 2221 • 2017 ACR/ARHP Annual Meeting
Eradication of Hepatitis C Among US Veterans: Examination of Changes in Pain Severity and Prescription Opioid Use Following Treatment
Anand Kumthekar¹, Sarah Shull², Benjamin Morasco^3,4, Travis Lovejoy^3,4, Michael Chang² and Jennifer Barton³, ¹Rheumatology, Oregon Health & Science University, Portland, OR, ²Gastroenterology, VA Portland Health Care System, Portland, OR, ³VA Portland Health Care System, Portland, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Hepatitis C virus (HCV) is associated with chronic wide spread pain, fatigue, myalgia, arthritis, sicca symptoms and vasculitis. Data regarding prior interferon-based treatment of…
Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Corinne Kowal¹, Carey Shive^2,3, Elizabeth Zebrowski^4,5, Lenche Kostadinova^1,6, Brianna Fuller^1,6, Elane Reyes², Kelsey Rife⁴, Amy Hirsch⁴, Anita Compan⁴, Shyam Kottilil⁷, Yngve Falck-Ytter^6,8, Leonard H. Calabrese⁹, Donald Anthony^4,6,10,11 and Maya Mattar^6,12, ¹Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, ²Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, ³VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH, ⁵Department of Medicine, Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University, Cleveland, OH, ⁷IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, ⁸Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, ⁹Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, ¹¹VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, ¹²Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
Abstract Number: 281 • 2017 ACR/ARHP Annual Meeting
Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France
Patrice Cacoub¹, Mathieu vautier², Anne-Claire Desbois³, David Saadoun⁴ and Zobair Younossi⁵, ¹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Médecine Interne 1, Hôpital Pitié-Salpêtrière, Paris, France, ³Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵Medicine, Inova Fairfax Hospital, Falls Church, Falls Church, VT
Background/Purpose: The economic impact of the extrahepatic manifestations (EHM) of hepatitis C virus (HCV) infection remains unknown for France. To estimate the prevalence of HCV-EHM…
Abstract Number: 894 • 2017 ACR/ARHP Annual Meeting
All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study
Patrice Cacoub¹, Si Nafa Si Ahmed², Yasmina FerFar³, SN Pol⁴, Dominique Thabut⁵, Christophe Hezode⁶, Laurent Albric⁷, Cloé Comarmond^8,9,10, Gafaar Ragab¹¹, Luca Quartuccio¹², Mohamed Hegazy¹³, Thierry Poynard⁵, Mathieu Resche-Rigon¹⁴ and David Saadoun¹⁵, ¹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Hôpital Orléans, Orléans, France, ³Internal Medicine, Hopital Pitié-Salpetrière, Paris, France, ⁴Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁵Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁶Hôpital Henri Mondor, Creteil, France, ⁷Centre hospitalier universitaire Purpan, Purpan, France, ⁸Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁰Internal Medicine, Hôpital Pitié Salpétrière, Paris, France, ¹¹Cairo University, Cairo, Egypt, ¹²University Hospital "Santa Maria della Misericordia, Udine, Italy, ¹³Faculty of Medicine – Cairo University, Cairo, El Salvador, ¹⁴Hôpital Saint-Louis, Paris, France, ¹⁵Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: Interferon (IFN) containing regimens used for hepatitis C virus (HCV)-cryoglobulinemia vasculitis (CryoVas) are poorly effective and associated with important side effects. In small-size and…
Abstract Number: 17L • 2016 ACR/ARHP Annual Meeting
Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
David Saadoun¹, yasmina ferfar¹, AS Bouyer², laurent alric³, christophe hezode⁴, SN Si Ahmed⁵, L Musset⁶, Luc De Saint Martin Pernot⁷, SN Pol⁸, Dominique Larrey⁹, T Poynard¹⁰ and Patrice Cacoub², ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, paris, France, ³Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse, toulouse, France, ⁴Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil, creteil, France, ⁵Department of Hepatology, Hôpital Orléans, Orléans, Orleans, France, ⁶Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, paris, France, ⁷Department of internal medicine, CHRU Brest, Brest, France, ⁸Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁹Department of hepatology, CHRU Montpellier, France, montpellier, France, ¹⁰Department of Hepatology, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, paris, France

Background/Purpose: Hepatitis C virus (HCV) is the aetiological agent for most cases of cryoglobulinemia vasculitis. Interferon containing regimens are associated with important side effects and…
Abstract Number: 1322 • 2016 ACR/ARHP Annual Meeting
Use of Biologics in Arthritis Patients with Hepatitis B and C ‏: A Multicentral Retrospective Case Series
Sultana Abdulaziz¹, Hessein Halabi², Mohammed Omair³, Suzan Attar⁴, Mohammed Shabrawishi⁵, Abdulwahab Neyazi⁶, Haneen Alnazzawi⁷, Noha Meraiani⁸ and Hani Almoallim⁹, ¹Dept of Medicine/Unit of Rheumatology, King Fahad Hospital, Jeddah, Saudi Arabia, ²Department of Medicine, King Faisal Specialist Hospital,, Jeddah, Saudi Arabia, ³Dept of Medicine, Div of Rheumatology, King Saud University, Riyadh, Saudi Arabia, ⁴Internal Medicine, FRCPC, ABIM, Professor in Medicine, Jeddah, Saudi Arabia, ⁵Department of Medicine, King Faisal Specialist Hospital, Jeddah, Saudi Arabia, ⁶Department of Medicine, King Abdullah Medical City, Jeddah, Saudi Arabia, ⁷King Faisal Specialist Hospital, JEDDAH, Saudi Arabia, ⁸Department of Medicine, National Guard Hospital, JEDDAH, Saudi Arabia, ⁹Department of Medicine, Umm Alqura University, Makkah, Saudi Arabia, Makkah, Saudi Arabia
Use of biologics in arthritis patients with Hepatitis B and C ‏: a multicentral retrospective case series Abstract Background/Purpose: Reactivation of viral hepatitis B…
Abstract Number: 2977 • 2016 ACR/ARHP Annual Meeting
Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols
Mohamed Tharwat Hegazy¹, Mohamed A Hussein¹, Luca Quartuccio², Mary Fawzy¹, Naguib Zoheir³, Mona I. Ellawindi⁴, Milena Bond², Cesare Mazzaro⁵, Ahmed El Ray⁶, Maissa El Said El Raziky^7,8, Magdy El Serafy⁹, Wahid Doss⁹, Patrice Cacoub¹⁰, Loïc Guillevin¹¹, Salvatore De Vita², Sherif El Khamisy¹² and Gaafar Ragab¹, ¹Internal Medicine, Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ³Clinical and Chemical Pathology Department, Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Community Medicine, Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁵Internal Medicine, Pordenone Hospital, Italy, pordenone, Italy, ⁶Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ⁷Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ⁸Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ⁹Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹²Zewail city of Science and Technology, Egypt, Giza, Egypt
Background/Purpose: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. Following emergence of direct acting antiviral drugs, which paved the way to…
Abstract Number: 1356 • 2015 ACR/ARHP Annual Meeting
Autoimmune Manifestations in Hepatitis C: A Single-Centered Experience
Azza Ali¹, Reshma Khan¹, Kirthi Lilley², Paul Naylor², Rajaie Namas¹ and Malini Venkatram¹, ¹Rheumatology, Wayne State University, Detroit, MI, ²Gastroenterology, Wayne State University, Detroit, MI
Background/Purpose: Hepatitis C infection (HCV) is a leading cause of chronic liver disease. It is associated with a plethora of autoimmune manifestations including clinical, serological…
Abstract Number: 1840 • 2015 ACR/ARHP Annual Meeting
How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?
Chandrahasa Annem¹, Joel A. Block² and Meenakshi Jolly³, ¹RHEUMATOLOGY, RUSH UNIVERSITY, CHICAGO, IL, ²Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Hepatitis B & C viral infections are widely prevalent and the potential of immunosuppressive medications (ISM) to exacerbate an underlying viral infection is well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].